The rise of new viruses, like SARS-CoV-2 causing the COVID-19 outbreak, along with the return of antibiotic resistance in harmful bacteria, demands a swift and efficient reaction to safeguard the health and welfare of...The rise of new viruses, like SARS-CoV-2 causing the COVID-19 outbreak, along with the return of antibiotic resistance in harmful bacteria, demands a swift and efficient reaction to safeguard the health and welfare of the global population. It is crucial to have effective measures for prevention, intervention, and monitoring in place to address these evolving and recurring risks, ensuring public health and international security. In countries with limited resources, utilizing recombinant mutation plasmid technology in conjunction with PCR-HRM could help differentiate the existence of novel variants. cDNA synthesis was carried out on 8 nasopharyngeal samples following viral RNA extraction. The P1 segment of the SARS-CoV-2 Spike S protein was amplified via conventional PCR. Subsequently, PCR products were ligated with the pGEM-T Easy vector to generate eight recombinant SARS-CoV-2 plasmids. Clones containing mutations were sequenced using Sanger sequencing and analyzed through PCR-HRM. The P1 segment of the S gene from SARS-CoV-2 was successfully amplified, resulting in 8 recombinant plasmids generated from the 231 bp fragment. PCR-HRM analysis of these recombinant plasmids differentiated three variations within the SARS-CoV-2 plasmid population, each displaying distinct melting temperatures. Sanger sequencing identified mutations A112C, G113T, A114G, G214T, and G216C on the P1 segment, validating the PCR-HRM findings of the variations. These mutations led to the detection of L452R or L452M and F486V protein mutations within the protein sequence of the Omicron variant of SARS-CoV-2. In summary, PCR-HRM is a vital and affordable tool for distinguishing SARS-CoV-2 variants utilizing recombinant plasmids as controls.展开更多
Potential mutagenic impurities in Active Pharmaceutical Ingredient, Meropenem Trihydrate were assessed and a novel analytical method for their quantification was developed and validated. This Liquid Chromatographic me...Potential mutagenic impurities in Active Pharmaceutical Ingredient, Meropenem Trihydrate were assessed and a novel analytical method for their quantification was developed and validated. This Liquid Chromatographic method using High Resolution Mass Spectrometer (LC-HRMS) technique is proved to be suitable for simultaneous quantification of all ten identified impurities with required specificity, sensitivity, resolution, precision, accuracy, and other method characteristics as per ICH Guidelines. The acceptable limit of less than 2.9 μg/g was considered for evaluations, based on drug substance dosage and duration of treatment. The method stands most sensitive with a Limit of Detection of 0.35 μg/g, considering the challenge full acceptance criteria as per current regulatory standards.展开更多
目的:探讨彝药黑根治疗类风湿性关节炎潜在的作用机制以及主要活性成分。方法:运用UPLC-Q-Orbitrap HRMS及GC-MS技术分析黑根的化学成分,利用Swiss Target进行活性成分的靶点筛选和预测,同时在Genecard、OMIM、Dis Ge NET等数据库中筛...目的:探讨彝药黑根治疗类风湿性关节炎潜在的作用机制以及主要活性成分。方法:运用UPLC-Q-Orbitrap HRMS及GC-MS技术分析黑根的化学成分,利用Swiss Target进行活性成分的靶点筛选和预测,同时在Genecard、OMIM、Dis Ge NET等数据库中筛选类风湿性关节炎相关靶点,利用Cytoscape3.9.0软件构建“活性成分-靶点”网络模型,运用String数据分析平台进行蛋白互作网络分析,并且利用基因富集分析在线工具对核心靶点进行GO富集分析和KEGG通路分析,最后使用分子对接对网络药理学内容进行初步验证。结果:共鉴定出黑根化学成分78个,筛选后活性成分50个,237个潜在作用靶点与类风湿性关节炎相关,包括STAT3、AKT1、EGFR等关键靶点。通路富集分析PI3K-Akt通路、JAK-STAT等信号通路可能是黑根发挥抗类风湿性关节炎的主要途径。通过分子对接技术得出主要活性成分(异绿原酸B、异绿原酸C)与关键靶点有较好结合力。结论:研究初步表明黑根通过多成分、多靶点、多途径治疗类风湿性关节炎的作用,为后续黑根物质基础研究提供了理论依据。展开更多
文摘The rise of new viruses, like SARS-CoV-2 causing the COVID-19 outbreak, along with the return of antibiotic resistance in harmful bacteria, demands a swift and efficient reaction to safeguard the health and welfare of the global population. It is crucial to have effective measures for prevention, intervention, and monitoring in place to address these evolving and recurring risks, ensuring public health and international security. In countries with limited resources, utilizing recombinant mutation plasmid technology in conjunction with PCR-HRM could help differentiate the existence of novel variants. cDNA synthesis was carried out on 8 nasopharyngeal samples following viral RNA extraction. The P1 segment of the SARS-CoV-2 Spike S protein was amplified via conventional PCR. Subsequently, PCR products were ligated with the pGEM-T Easy vector to generate eight recombinant SARS-CoV-2 plasmids. Clones containing mutations were sequenced using Sanger sequencing and analyzed through PCR-HRM. The P1 segment of the S gene from SARS-CoV-2 was successfully amplified, resulting in 8 recombinant plasmids generated from the 231 bp fragment. PCR-HRM analysis of these recombinant plasmids differentiated three variations within the SARS-CoV-2 plasmid population, each displaying distinct melting temperatures. Sanger sequencing identified mutations A112C, G113T, A114G, G214T, and G216C on the P1 segment, validating the PCR-HRM findings of the variations. These mutations led to the detection of L452R or L452M and F486V protein mutations within the protein sequence of the Omicron variant of SARS-CoV-2. In summary, PCR-HRM is a vital and affordable tool for distinguishing SARS-CoV-2 variants utilizing recombinant plasmids as controls.
文摘Potential mutagenic impurities in Active Pharmaceutical Ingredient, Meropenem Trihydrate were assessed and a novel analytical method for their quantification was developed and validated. This Liquid Chromatographic method using High Resolution Mass Spectrometer (LC-HRMS) technique is proved to be suitable for simultaneous quantification of all ten identified impurities with required specificity, sensitivity, resolution, precision, accuracy, and other method characteristics as per ICH Guidelines. The acceptable limit of less than 2.9 μg/g was considered for evaluations, based on drug substance dosage and duration of treatment. The method stands most sensitive with a Limit of Detection of 0.35 μg/g, considering the challenge full acceptance criteria as per current regulatory standards.
文摘目的:探讨彝药黑根治疗类风湿性关节炎潜在的作用机制以及主要活性成分。方法:运用UPLC-Q-Orbitrap HRMS及GC-MS技术分析黑根的化学成分,利用Swiss Target进行活性成分的靶点筛选和预测,同时在Genecard、OMIM、Dis Ge NET等数据库中筛选类风湿性关节炎相关靶点,利用Cytoscape3.9.0软件构建“活性成分-靶点”网络模型,运用String数据分析平台进行蛋白互作网络分析,并且利用基因富集分析在线工具对核心靶点进行GO富集分析和KEGG通路分析,最后使用分子对接对网络药理学内容进行初步验证。结果:共鉴定出黑根化学成分78个,筛选后活性成分50个,237个潜在作用靶点与类风湿性关节炎相关,包括STAT3、AKT1、EGFR等关键靶点。通路富集分析PI3K-Akt通路、JAK-STAT等信号通路可能是黑根发挥抗类风湿性关节炎的主要途径。通过分子对接技术得出主要活性成分(异绿原酸B、异绿原酸C)与关键靶点有较好结合力。结论:研究初步表明黑根通过多成分、多靶点、多途径治疗类风湿性关节炎的作用,为后续黑根物质基础研究提供了理论依据。
